Reversal of P-glycoprotein-associated multidrug resistance by ivermectin

Biochemical Pharmacology

Volumn 53, Issue 1, 1997, Pages 17-25

  Pouliot, Jean François ^a   L'Heureux, Françoise ^a   Liu, Zhi ^a   Prichard, Roger K ^a   Georges, Elias ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

ivermectin; multidrug resistance; P glycoprotein

Indexed keywords

ANTHELMINTIC AGENT; COLCHICINE; CYCLOSPORIN A; DOXORUBICIN; GLYCOPROTEIN P; IVERMECTIN; MULTIDRUG RESISTANCE REVERSING AGENT; RADIOISOTOPE; UNCLASSIFIED DRUG; VALSPODAR; VERAPAMIL; VINBLASTINE;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG TRANSPORT; HUMAN; HUMAN CELL; MEMBRANE BINDING; MULTIDRUG RESISTANCE; PHENOTYPE; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; TUMOR CELL LINE;

AFFINITY LABELS; CELLS, CULTURED; DRUG RESISTANCE, MULTIPLE; HUMANS; IVERMECTIN; P-GLYCOPROTEIN; VINBLASTINE;

EID: 0031060625     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(96)00656-9     Document Type: Article

References (38)

1. Endicott JA and Ling V, The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58: 137-171, 1989.
2. Gottesman MM and Pastan I, Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu Rev Biochem 62: 385-427, 1993.
3. Cole SPC, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM and Deeley RG, Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54: 5902-5910, 1994.
4. Riordan JR, Deuchars K, Kartner N, Alon N, Trent J and Ling V, Amplification of P-glycoprotein genes in multidrug-resistant mammalian cell lines. Nature 316: 817-819, 1985.
5. Higgins CF, ABC transporters: From microorganisms to man. Annu Rev Cell Biol 8: 67-113, 1992.
6. Smit JJM, Schinkel AH, Oude Elferink RPJ, Groen AK, Wagenaar E, van Deemter L, Mol CAAM, Ottenhoff R, van der Lugt NMT, van Roon MA, van der Valk MA, Offerhaus GJA, Berns AJM and Borst P, Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease. Cell 75: 451-462, 1993.
7. Ruetz S and Gros P, Phosphatidylcholine translocase - A physiological-role for the mdr2 gene. Cell 77: 1071-1081, 1994.
8. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai S-L, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM, Lieber M, Cossman J, Gottesman MM and Pastan I, Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 81: 116-124, 1989.
9. Chan HSL, Haddad G, Thorner PS, DeBoer G, Lin YP, Ondrusek N, Yeger H and Ling V, P-Glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N Engl J Med 325: 1608-1614, 1991.
10. Chan HS, DeBoer G, Haddad G, Gallie BL and Ling V, Multidrug resistance in pediatric malignancies. Hematol Oncol Clin North Am 9: 275-318, 1995.
11. Patel NH and Rothenberg ML, Multidrug resistance in cancer chemotherapy. Invest New Drugs 12: 1-13, 1994.
12. Ozols RF, Clinical reversal of drug resistance - Foreword. Curr Probl Cancer 19: 69-123, 1995.
13. Ford JM, Modulators of multidrug resistance. Preclinical studies. Hematol Oncol Clin North Am 9: 337-361, 1995.
14. Pennock GD, Dalton WS, Roeske WR, Appleton CP, Mosley K, Plezia P, Miller TP and Salmon SE, Systemic toxic effects associated with high-dose verapamil infusion and chemotherapy administration. J Natl Cancer Inst 83: 105-110, 1991.
15. Dalton WS, Crowley JJ, Salmon SS, Grogan TM, Laufman LR, Weiss GR and Bonnett JD, A phase III randomized study of oral verapamil as a chemosensitizer to reverse drug resistance in patients with refractory myeloma. Cancer 75: 815-820, 1995.
16. Murren JR, Ganpule S, Sarris A, Durivage H, Davis C, Makuch R, Handschumacher RE and Marsh JC, A phase II trial of cyclosporin A in the treatment of refractory metastatic colorectal cancer. Am J Clin Oncol 14: 208-210, 1991.
17. Warner E, Tobe SW, Andrulis IL, Pei Y, Trachtenberg J and Skorecki KL, Phase I-II study of vinblastine and oral cyclosporin A in metastatic renal cell carcinoma. Am J Clin Oncol 18: 251-256, 1995.
18. Campbell WC, Ivermectin and Abamectin. Springer, New York, 1989.
19. Cully DF, Vassilatis DK, Liu KK, Paress PS, Van der Ploeg LHT, Schaeffer JM and Arena JP, Cloning of an avermectin-sensitive glutamate-gated chloride channel from Caenorhabditis elegans. Nature 371: 707-711, 1994.
20. Cully DF and Paress PS, Solubilization and characterization of a high affinity ivermectin hinding site from Caenorhabditis elegans. Mol Pharmacol 40: 326-332, 1991.
21. Schaeffer JM and Haines HW, Avermectin binding in Caenorhabditis elegans. A two-state model for the avermectin binding site. Biochem Pharmacol 38: 2329-2338, 1989.
22. Chiu S-HL, Green ML, Baylis FP, Eline D, Rosegay A, Meriwether H and Jacob TA, Absorption, tissue distribution, and excretion of tritium-labeled ivermectin in cattle, sheep and rat. J Agric Food Chem 38: 2072-2078, 1990.
23. Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CAAM, van der Valk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM and Borst P, Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491-502, 1994.
24. Beck WT, Vinca alkaloid-resistant phenotype in cultured human leukemic lymphoblasts. Cancer Treat Rep 67: 875-882, 1983.
25. Zordan-Nudo T, Ling GV, Liu Z and Georges E, Effects of nonionic detergents on P-glycoprotein drug binding and reversal of multidrug resistance. Cancer Res 53: 5994-6000, 1993.
26. Lin PH, Selinfreund R, Wakshull E and Wharton W, Rapid and efficient purification of plasma membrane from cultured cells: Characterization of epidermal growth factor binding. Biochemistry 26: 731-736, 1987.
27. Bradford MM, A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
28. Fairbanks G, Steck TL and Wallach DFH, Electrophoretic analysis of major polypeptides of the human erythrocyte membrane. Biochemistry 10: 2606-2617, 1971.
29. 1,-adrenergic receptor and the calcium channel bind to a common domain in P-glycoprotein. J Biol Chem 265: 4394-4401, 1990.
30. Pearce HL, Safa AR, Bach NJ, Winter MA, Cirtain MC and Beck WT, Essential features of the P-glycoprotein pharmacophore as defined by a series of reserpine analogs that modulate multidrug resistance. Proc Natl Acad Sci USA 86: 5128-5132, 1989.
31. Watanabe T, Tsuge H, Oh-Hara T, Naito M and Tsuruo T, Comparative study on reversal efficacy of SDZ PSC 833, cyclosporin A and verapamil on multidrug resistance in vitro and in vivo. Acta Oncol 34: 235-241, 1995.
32. Cornwell MM, Pastan I and Gottesman MM, Certain calcium channel blockers bind specifically to multidrug-resistant human KB carcinoma membrane vesicles and inhibit drug binding to P-glycoprotein. J Biol Chem 262: 2166-2170, 1987.
33. 2+-dependent binding of vincristine to the plasma membrane of multidrug-resistant K562 cells. J Biol Chem 263: 11887-11891, 1988.
34. Zamora JM, Pearce HL and Beck WT, Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells. Mol Pharmacol 33: 454-462, 1988.
35. Nogae I, Kohno K, Kikuchi J, Kuwano M, Akiyama S, Kiue A, Suzuki K, Yoshida Y, Cornwell MM, Pastan I and Gottesman MM, Analysis of structural features of dihydropyridine analogs needed to reverse multidrug resistance and to inhibit photoaffinity labeling of P-glycoprotein. Biochem Pharmacol 38: 519-527, 1989.
36. Nare B, Prichard RK and Georges E, Characterization of rhodamine 123 binding to P-glycoprotein in human multidrug-resistant cells. Mol Pharmacol 45: 1145-1152, 1994.
37. Foxwell BM, Mackie A, Ling V and Ryffel B, Identification of the multidrug resistance-related P-glycoprotein as a cyclosporine binding protein. Mol Pharmacol 36: 543-546, 1989.
38. Greenberger LM, Major photoaffinity drug labeling sites for iodoaryl azidoprazosin in P-glycoprotein are within, or immediately C-terminal to, transmembrane domains 6 and 12. J Biol Chem 268: 11471-11475, 1993.